Ultrasound7 versus ultrasound12 in monitoring the response to infliximab in patients with rheumatoid arthritis
This study aimed to assess the responsiveness of ultrasonography (US)-7 in patients with rheumatoid arthritis (RA). Eighty-two RA patients were recruited and followed up for 22 weeks. The clinical, laboratory, and X-ray assessments, along with grayscale US (GSUS) and power Doppler US (PDUS) examinat...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 2016-03, Vol.35 (3), p.587-594 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 594 |
|---|---|
| container_issue | 3 |
| container_start_page | 587 |
| container_title | Clinical rheumatology |
| container_volume | 35 |
| creator | Leng, Xiaomei Xiao, Weiguo Xu, Zhonghui Zhu, Xiaochun Liu, Yi Zhao, Dongbao Xu, Huji Chen, Guoqiang Yu, Wei Lu, Jing Wang, Jiakai Xia, Xiaoru Li, Yongji Zhao, Yi Tang, Honghu Shi, Yeqing Bao, Jun Chen, Ling Lin, Li Zhou, Ling Zhang, Hongwei Zhao, Yan |
| description | This study aimed to assess the responsiveness of ultrasonography (US)-7 in patients with rheumatoid arthritis (RA). Eighty-two RA patients were recruited and followed up for 22 weeks. The clinical, laboratory, and X-ray assessments, along with grayscale US (GSUS) and power Doppler US (PDUS) examinations were performed at baseline, 6, 14, and 22 weeks after infliximab treatment. GSUS for synovitis and PDUS for synovitis and paratendinitis/tenosynovitis were assessed by a semi-quantitative (0 to 3) score, while GSUS for paratendinitis/tenosynovitis and bone erosion was qualitatively assessed as absent or present (0 or 1). US scores in both 7-joint (US7) and 12-joint (US12) systems were evaluated. After 6, 14, and 22 weeks of treatment with infliximab, indices such as US scores, 28-joint disease activity (DAS28) score, and tender and swelling joint count were all significantly improved compared to baseline. US7 scores were significantly correlated with that of US12. Strong correlations were identified between most US7 scores with DAS28, health assessment questionnaire (HAQ), and C-reactive protein (CRP) levels. When DAS28 was used as a reference, the US7 cutoff for disease remission was less than 35 for GS + PD and also less than 29 for GS and 1 for PD, respectively. Additionally, the positive percent agreement, negative percent agreement, and overall percent agreement for GS + PD were 77.78, 76.19, and 76.67 %, respectively, which were all higher than that of GS or PD. US7 may be a feasible tool to assess the therapeutic response in RA patients. |
| doi_str_mv | 10.1007/s10067-016-3176-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1772837127</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1772837127</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-cd021f7160674b71fbffd9cd7a0bd1bd40ba78864ab6dcab11cc26a8415a0c1d3</originalsourceid><addsrcrecordid>eNp1kV1LHTEQhkNp0aP1B_SmBHrjzdZMTtzsXhZpVRC80euQr-2J7CbbTLa1_94sR6UUhDCBzDNvZuYl5BOwr8CYPMMaW9kwaJstyLbh78gGxFY0fS_692TDpGQ103eH5AjxgTHGux4OyCFvZQeyO9-QeD-WrDEt0Un622dckC6vT8BpiHRKMZSUQ_xJy87T7HFOET0tqWaHMTyGSZsVnHUJPhakf0LZ0bzzy6RLCo7qXHY5lIAfyYdBj-hPnu9jcv_j-93FVXNze3l98e2msULw0ljHOAwS2jqeMBIGMwyut05qZhwYJ5jRsutaoU3rrDYA1vJWdwLONbPgtsfkdK875_Rr8VjUFND6cdTRpwUVSMm7rQQuK_rlP_QhLTnW7laqnl6IvlKwp2xOiNkPas517PxXAVOrGWpvhqpmqNUMxWvN52flxUzevVa8bL8CfA_gvG7X53--flP1CWFplxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1771779449</pqid></control><display><type>article</type><title>Ultrasound7 versus ultrasound12 in monitoring the response to infliximab in patients with rheumatoid arthritis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Leng, Xiaomei ; Xiao, Weiguo ; Xu, Zhonghui ; Zhu, Xiaochun ; Liu, Yi ; Zhao, Dongbao ; Xu, Huji ; Chen, Guoqiang ; Yu, Wei ; Lu, Jing ; Wang, Jiakai ; Xia, Xiaoru ; Li, Yongji ; Zhao, Yi ; Tang, Honghu ; Shi, Yeqing ; Bao, Jun ; Chen, Ling ; Lin, Li ; Zhou, Ling ; Zhang, Hongwei ; Zhao, Yan</creator><creatorcontrib>Leng, Xiaomei ; Xiao, Weiguo ; Xu, Zhonghui ; Zhu, Xiaochun ; Liu, Yi ; Zhao, Dongbao ; Xu, Huji ; Chen, Guoqiang ; Yu, Wei ; Lu, Jing ; Wang, Jiakai ; Xia, Xiaoru ; Li, Yongji ; Zhao, Yi ; Tang, Honghu ; Shi, Yeqing ; Bao, Jun ; Chen, Ling ; Lin, Li ; Zhou, Ling ; Zhang, Hongwei ; Zhao, Yan</creatorcontrib><description>This study aimed to assess the responsiveness of ultrasonography (US)-7 in patients with rheumatoid arthritis (RA). Eighty-two RA patients were recruited and followed up for 22 weeks. The clinical, laboratory, and X-ray assessments, along with grayscale US (GSUS) and power Doppler US (PDUS) examinations were performed at baseline, 6, 14, and 22 weeks after infliximab treatment. GSUS for synovitis and PDUS for synovitis and paratendinitis/tenosynovitis were assessed by a semi-quantitative (0 to 3) score, while GSUS for paratendinitis/tenosynovitis and bone erosion was qualitatively assessed as absent or present (0 or 1). US scores in both 7-joint (US7) and 12-joint (US12) systems were evaluated. After 6, 14, and 22 weeks of treatment with infliximab, indices such as US scores, 28-joint disease activity (DAS28) score, and tender and swelling joint count were all significantly improved compared to baseline. US7 scores were significantly correlated with that of US12. Strong correlations were identified between most US7 scores with DAS28, health assessment questionnaire (HAQ), and C-reactive protein (CRP) levels. When DAS28 was used as a reference, the US7 cutoff for disease remission was less than 35 for GS + PD and also less than 29 for GS and 1 for PD, respectively. Additionally, the positive percent agreement, negative percent agreement, and overall percent agreement for GS + PD were 77.78, 76.19, and 76.67 %, respectively, which were all higher than that of GS or PD. US7 may be a feasible tool to assess the therapeutic response in RA patients.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-016-3176-2</identifier><identifier>PMID: 26781785</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Adult ; Aged ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - diagnostic imaging ; Arthritis, Rheumatoid - drug therapy ; Female ; Hand Joints - diagnostic imaging ; Humans ; Infliximab - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Original Article ; Rheumatology ; Severity of Illness Index ; Treatment Outcome ; Ultrasonography - methods ; Young Adult</subject><ispartof>Clinical rheumatology, 2016-03, Vol.35 (3), p.587-594</ispartof><rights>International League of Associations for Rheumatology (ILAR) 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-cd021f7160674b71fbffd9cd7a0bd1bd40ba78864ab6dcab11cc26a8415a0c1d3</citedby><cites>FETCH-LOGICAL-c442t-cd021f7160674b71fbffd9cd7a0bd1bd40ba78864ab6dcab11cc26a8415a0c1d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-016-3176-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-016-3176-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26781785$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leng, Xiaomei</creatorcontrib><creatorcontrib>Xiao, Weiguo</creatorcontrib><creatorcontrib>Xu, Zhonghui</creatorcontrib><creatorcontrib>Zhu, Xiaochun</creatorcontrib><creatorcontrib>Liu, Yi</creatorcontrib><creatorcontrib>Zhao, Dongbao</creatorcontrib><creatorcontrib>Xu, Huji</creatorcontrib><creatorcontrib>Chen, Guoqiang</creatorcontrib><creatorcontrib>Yu, Wei</creatorcontrib><creatorcontrib>Lu, Jing</creatorcontrib><creatorcontrib>Wang, Jiakai</creatorcontrib><creatorcontrib>Xia, Xiaoru</creatorcontrib><creatorcontrib>Li, Yongji</creatorcontrib><creatorcontrib>Zhao, Yi</creatorcontrib><creatorcontrib>Tang, Honghu</creatorcontrib><creatorcontrib>Shi, Yeqing</creatorcontrib><creatorcontrib>Bao, Jun</creatorcontrib><creatorcontrib>Chen, Ling</creatorcontrib><creatorcontrib>Lin, Li</creatorcontrib><creatorcontrib>Zhou, Ling</creatorcontrib><creatorcontrib>Zhang, Hongwei</creatorcontrib><creatorcontrib>Zhao, Yan</creatorcontrib><title>Ultrasound7 versus ultrasound12 in monitoring the response to infliximab in patients with rheumatoid arthritis</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>This study aimed to assess the responsiveness of ultrasonography (US)-7 in patients with rheumatoid arthritis (RA). Eighty-two RA patients were recruited and followed up for 22 weeks. The clinical, laboratory, and X-ray assessments, along with grayscale US (GSUS) and power Doppler US (PDUS) examinations were performed at baseline, 6, 14, and 22 weeks after infliximab treatment. GSUS for synovitis and PDUS for synovitis and paratendinitis/tenosynovitis were assessed by a semi-quantitative (0 to 3) score, while GSUS for paratendinitis/tenosynovitis and bone erosion was qualitatively assessed as absent or present (0 or 1). US scores in both 7-joint (US7) and 12-joint (US12) systems were evaluated. After 6, 14, and 22 weeks of treatment with infliximab, indices such as US scores, 28-joint disease activity (DAS28) score, and tender and swelling joint count were all significantly improved compared to baseline. US7 scores were significantly correlated with that of US12. Strong correlations were identified between most US7 scores with DAS28, health assessment questionnaire (HAQ), and C-reactive protein (CRP) levels. When DAS28 was used as a reference, the US7 cutoff for disease remission was less than 35 for GS + PD and also less than 29 for GS and 1 for PD, respectively. Additionally, the positive percent agreement, negative percent agreement, and overall percent agreement for GS + PD were 77.78, 76.19, and 76.67 %, respectively, which were all higher than that of GS or PD. US7 may be a feasible tool to assess the therapeutic response in RA patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - diagnostic imaging</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Female</subject><subject>Hand Joints - diagnostic imaging</subject><subject>Humans</subject><subject>Infliximab - therapeutic use</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Rheumatology</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Ultrasonography - methods</subject><subject>Young Adult</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kV1LHTEQhkNp0aP1B_SmBHrjzdZMTtzsXhZpVRC80euQr-2J7CbbTLa1_94sR6UUhDCBzDNvZuYl5BOwr8CYPMMaW9kwaJstyLbh78gGxFY0fS_692TDpGQ103eH5AjxgTHGux4OyCFvZQeyO9-QeD-WrDEt0Un622dckC6vT8BpiHRKMZSUQ_xJy87T7HFOET0tqWaHMTyGSZsVnHUJPhakf0LZ0bzzy6RLCo7qXHY5lIAfyYdBj-hPnu9jcv_j-93FVXNze3l98e2msULw0ljHOAwS2jqeMBIGMwyut05qZhwYJ5jRsutaoU3rrDYA1vJWdwLONbPgtsfkdK875_Rr8VjUFND6cdTRpwUVSMm7rQQuK_rlP_QhLTnW7laqnl6IvlKwp2xOiNkPas517PxXAVOrGWpvhqpmqNUMxWvN52flxUzevVa8bL8CfA_gvG7X53--flP1CWFplxQ</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Leng, Xiaomei</creator><creator>Xiao, Weiguo</creator><creator>Xu, Zhonghui</creator><creator>Zhu, Xiaochun</creator><creator>Liu, Yi</creator><creator>Zhao, Dongbao</creator><creator>Xu, Huji</creator><creator>Chen, Guoqiang</creator><creator>Yu, Wei</creator><creator>Lu, Jing</creator><creator>Wang, Jiakai</creator><creator>Xia, Xiaoru</creator><creator>Li, Yongji</creator><creator>Zhao, Yi</creator><creator>Tang, Honghu</creator><creator>Shi, Yeqing</creator><creator>Bao, Jun</creator><creator>Chen, Ling</creator><creator>Lin, Li</creator><creator>Zhou, Ling</creator><creator>Zhang, Hongwei</creator><creator>Zhao, Yan</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160301</creationdate><title>Ultrasound7 versus ultrasound12 in monitoring the response to infliximab in patients with rheumatoid arthritis</title><author>Leng, Xiaomei ; Xiao, Weiguo ; Xu, Zhonghui ; Zhu, Xiaochun ; Liu, Yi ; Zhao, Dongbao ; Xu, Huji ; Chen, Guoqiang ; Yu, Wei ; Lu, Jing ; Wang, Jiakai ; Xia, Xiaoru ; Li, Yongji ; Zhao, Yi ; Tang, Honghu ; Shi, Yeqing ; Bao, Jun ; Chen, Ling ; Lin, Li ; Zhou, Ling ; Zhang, Hongwei ; Zhao, Yan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-cd021f7160674b71fbffd9cd7a0bd1bd40ba78864ab6dcab11cc26a8415a0c1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - diagnostic imaging</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Female</topic><topic>Hand Joints - diagnostic imaging</topic><topic>Humans</topic><topic>Infliximab - therapeutic use</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Rheumatology</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Ultrasonography - methods</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leng, Xiaomei</creatorcontrib><creatorcontrib>Xiao, Weiguo</creatorcontrib><creatorcontrib>Xu, Zhonghui</creatorcontrib><creatorcontrib>Zhu, Xiaochun</creatorcontrib><creatorcontrib>Liu, Yi</creatorcontrib><creatorcontrib>Zhao, Dongbao</creatorcontrib><creatorcontrib>Xu, Huji</creatorcontrib><creatorcontrib>Chen, Guoqiang</creatorcontrib><creatorcontrib>Yu, Wei</creatorcontrib><creatorcontrib>Lu, Jing</creatorcontrib><creatorcontrib>Wang, Jiakai</creatorcontrib><creatorcontrib>Xia, Xiaoru</creatorcontrib><creatorcontrib>Li, Yongji</creatorcontrib><creatorcontrib>Zhao, Yi</creatorcontrib><creatorcontrib>Tang, Honghu</creatorcontrib><creatorcontrib>Shi, Yeqing</creatorcontrib><creatorcontrib>Bao, Jun</creatorcontrib><creatorcontrib>Chen, Ling</creatorcontrib><creatorcontrib>Lin, Li</creatorcontrib><creatorcontrib>Zhou, Ling</creatorcontrib><creatorcontrib>Zhang, Hongwei</creatorcontrib><creatorcontrib>Zhao, Yan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leng, Xiaomei</au><au>Xiao, Weiguo</au><au>Xu, Zhonghui</au><au>Zhu, Xiaochun</au><au>Liu, Yi</au><au>Zhao, Dongbao</au><au>Xu, Huji</au><au>Chen, Guoqiang</au><au>Yu, Wei</au><au>Lu, Jing</au><au>Wang, Jiakai</au><au>Xia, Xiaoru</au><au>Li, Yongji</au><au>Zhao, Yi</au><au>Tang, Honghu</au><au>Shi, Yeqing</au><au>Bao, Jun</au><au>Chen, Ling</au><au>Lin, Li</au><au>Zhou, Ling</au><au>Zhang, Hongwei</au><au>Zhao, Yan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ultrasound7 versus ultrasound12 in monitoring the response to infliximab in patients with rheumatoid arthritis</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>35</volume><issue>3</issue><spage>587</spage><epage>594</epage><pages>587-594</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>This study aimed to assess the responsiveness of ultrasonography (US)-7 in patients with rheumatoid arthritis (RA). Eighty-two RA patients were recruited and followed up for 22 weeks. The clinical, laboratory, and X-ray assessments, along with grayscale US (GSUS) and power Doppler US (PDUS) examinations were performed at baseline, 6, 14, and 22 weeks after infliximab treatment. GSUS for synovitis and PDUS for synovitis and paratendinitis/tenosynovitis were assessed by a semi-quantitative (0 to 3) score, while GSUS for paratendinitis/tenosynovitis and bone erosion was qualitatively assessed as absent or present (0 or 1). US scores in both 7-joint (US7) and 12-joint (US12) systems were evaluated. After 6, 14, and 22 weeks of treatment with infliximab, indices such as US scores, 28-joint disease activity (DAS28) score, and tender and swelling joint count were all significantly improved compared to baseline. US7 scores were significantly correlated with that of US12. Strong correlations were identified between most US7 scores with DAS28, health assessment questionnaire (HAQ), and C-reactive protein (CRP) levels. When DAS28 was used as a reference, the US7 cutoff for disease remission was less than 35 for GS + PD and also less than 29 for GS and 1 for PD, respectively. Additionally, the positive percent agreement, negative percent agreement, and overall percent agreement for GS + PD were 77.78, 76.19, and 76.67 %, respectively, which were all higher than that of GS or PD. US7 may be a feasible tool to assess the therapeutic response in RA patients.</abstract><cop>London</cop><pub>Springer London</pub><pmid>26781785</pmid><doi>10.1007/s10067-016-3176-2</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2016-03, Vol.35 (3), p.587-594 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1772837127 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - diagnostic imaging Arthritis, Rheumatoid - drug therapy Female Hand Joints - diagnostic imaging Humans Infliximab - therapeutic use Male Medicine Medicine & Public Health Middle Aged Original Article Rheumatology Severity of Illness Index Treatment Outcome Ultrasonography - methods Young Adult |
| title | Ultrasound7 versus ultrasound12 in monitoring the response to infliximab in patients with rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A34%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ultrasound7%20versus%20ultrasound12%20in%20monitoring%20the%20response%20to%20infliximab%20in%20patients%20with%20rheumatoid%20arthritis&rft.jtitle=Clinical%20rheumatology&rft.au=Leng,%20Xiaomei&rft.date=2016-03-01&rft.volume=35&rft.issue=3&rft.spage=587&rft.epage=594&rft.pages=587-594&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-016-3176-2&rft_dat=%3Cproquest_cross%3E1772837127%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1771779449&rft_id=info:pmid/26781785&rfr_iscdi=true |